PDCD1 and Miyoshi myopathy: Additionally, anti-PD1 antibody may increase migration of NK cells toward MM targets and enhances immune complex formation between NK cells and PD-L1–bearing tumor cells [40], which may improve treatment efficacy of NK cells in vivo.